NCT07238127Not yet recruiting
AST/ALT & MPV/Platelets Ratios in Breast Cancer
Role of AST/ALT Ratio & MPV/Platelets Count Ratio in Breast Cancer
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
This retrospective study aims to evaluate the association between AST/ALT ratio and MPV/platelets count ratio with breast cancer in a case-control study.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 110 (estimated)
- First submitted
- 16 Nov 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Assiut University
- Diseases
- Childhood cancers
- NCT number
- NCT07238127
What you commit to
- Study type: Observational
- Planned participants: 110
- From 1 Jan 2026 to the primary completion date, 1 Nov 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- other malignant diseases
- male breast cancer
Who the study is looking for
- Newly diagnosed patients of breast cancer admitted to South Egypt Cancer Institute at different stage of the disease
Sex: Female · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.